The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab with or without the pertuzumab combination. How...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biomolecules
Main Authors: Shin, Jung Won, Kim, Soohyun, Ha, Suji, Choi, Byungsan, Kim, Seongyeong, Im, Seock-Ah, Yoon, Tae-Young, Chung, Junho
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843359/
https://ncbi.nlm.nih.gov/pubmed/31635022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom9100629
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares